SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ambros Therapeutics Plans Interim Analysis of Phase 3 Trial After FDA Feedback

The company plans a group sequential design with an interim analysis that could allow the trial to stop early.

Related stories